<DOC>
	<DOCNO>NCT02826005</DOCNO>
	<brief_summary>Examination ability early diagnose HCC combine three biomarkers technology develop WAKO , And relevance cirrhotic patient various background Israeli population . This blood test serve additional diagnostic tool tool currently use ( Ultrasound AFP level ) cirrhotic patient high risk develop hepatocellular carcinoma . Another group examine three biomarkers patient already diagnose hepatocellular carcinoma , normal AFP level order examine correlation presence tumor , number tumor size three biomarkers concentration blood</brief_summary>
	<brief_title>Examination Ability Early Diagnose HCC Combining Three Biomarkers Technology Developed WAKO , And Their Relevance Cirrhotic Patients With Various Backgrounds Israeli Population .</brief_title>
	<detailed_description />
	<criteria>patient chronic liver disease cirrhotic diagnosis HCC HCV , HBV , NAFLD , Alcohol background patient chronic liver disease cirrhotic diagnosis HCC autoimmune background background HCV , HBV , NAFLD Alcohol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>